To compare the prevalence of abnormal anal cytology and
high-risk human papillomavirus (HPV) among women with a history of HPV-related
genital neoplasia with women without a history of HPV-related genital neoplasia.
A cross-sectional cohort study was performed from December
2012 to February 2014. Women were recruited from outpatient clinics at an
academic medical center. Women with a history of high-grade cervical, vulvar,
or vaginal cytology, dysplasia, or cancer were considered the high-risk group.
Women with no history of high-grade anogenital dysplasia or cancer were
considered the low-risk group. Human immunodeficiency virus-positive women were
excluded. Anal cytology and HPV genotyping were performed. Women with abnormal
anal cytology were referred for high-resolution anoscopy.
There were 190 women in the high-risk group and 83 in the
low-risk group. The high-risk group was slightly older: 57 years compared with
47 years (P=.045); 21.7% of low-risk women had abnormal anal cytology compared
with 41.2% of high-risk women (P=.006). High-risk HPV was detected in the anal
canal of 1.2% of the low-risk group compared with 20.8% of the high-risk group
(P<.001). Among women who underwent anoscopy, no anal dysplasia was detected
in the low-risk group, whereas 13.4% in the high-risk group had anal dysplasia
with 4.2% having anal intraepithelial neoplasia 2 or greater (P<.001).
Human immunodeficiency virus-negative women with a history
of lower genital tract neoplasia are more likely to have positive anal
cytology, anal high-risk HPV, and anal intraepithelial neoplasia. Anal cancer
screening should be considered for these high-risk women.
Purchase full article at: http://goo.gl/6Qgrqj
By: Robison K1, Cronin B, Bregar A, Luis C, DiSilvestro P, Schechter S, Pisharodi L, Raker C, Clark M.
- 1Women & Infants Hospital, the Department of Pathology, the Warren Alpert Medical School of Brown University, the Program in Women's Oncology, University Surgical Associates, and the Division of Research and Department of Epidemiology, Brown University, School of Public Health, Providence, Rhode Island.
More at: https://twitter.com/hiv_insight
No comments:
Post a Comment